PL2310044T3 - Immunoterapia przeciwnowotworowa - Google Patents

Immunoterapia przeciwnowotworowa

Info

Publication number
PL2310044T3
PL2310044T3 PL09776746T PL09776746T PL2310044T3 PL 2310044 T3 PL2310044 T3 PL 2310044T3 PL 09776746 T PL09776746 T PL 09776746T PL 09776746 T PL09776746 T PL 09776746T PL 2310044 T3 PL2310044 T3 PL 2310044T3
Authority
PL
Poland
Prior art keywords
tumor immunotherapy
immunotherapy
tumor
Prior art date
Application number
PL09776746T
Other languages
English (en)
Inventor
Gilberto Filaci
Francesco Indiveri
Paolo Traverso
Original Assignee
Mediolanum Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediolanum Farmaceutici S.P.A. filed Critical Mediolanum Farmaceutici S.P.A.
Publication of PL2310044T3 publication Critical patent/PL2310044T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL09776746T 2008-06-16 2009-06-16 Immunoterapia przeciwnowotworowa PL2310044T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6177808P 2008-06-16 2008-06-16

Publications (1)

Publication Number Publication Date
PL2310044T3 true PL2310044T3 (pl) 2017-04-28

Family

ID=41507473

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09776746T PL2310044T3 (pl) 2008-06-16 2009-06-16 Immunoterapia przeciwnowotworowa

Country Status (14)

Country Link
US (1) US8828403B2 (pl)
EP (1) EP2310044B1 (pl)
JP (1) JP5787752B2 (pl)
CA (1) CA2727388C (pl)
CY (1) CY1118215T1 (pl)
DK (1) DK2310044T3 (pl)
ES (1) ES2602453T3 (pl)
HR (1) HRP20161434T1 (pl)
HU (1) HUE030984T2 (pl)
LT (1) LT2310044T (pl)
PL (1) PL2310044T3 (pl)
PT (1) PT2310044T (pl)
SI (1) SI2310044T1 (pl)
WO (1) WO2010003520A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2536830T3 (pl) 2010-02-16 2020-02-28 Ultimovacs As Polipeptydy
WO2013169077A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 악액질 예방 또는 치료용 조성물
CN104507961B (zh) * 2012-05-11 2018-08-14 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
WO2014046481A1 (ko) * 2012-09-19 2014-03-27 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
CN110074997B (zh) * 2012-09-19 2022-07-08 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
KR102093093B1 (ko) * 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
US9907838B2 (en) 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
JP6059405B2 (ja) 2013-06-07 2017-01-11 ジェムバックス アンド カエル カンパニー，リミティド 癌の免疫学的治療に有用な生物学的マーカー
WO2014204281A1 (ko) * 2013-06-21 2014-12-24 주식회사 카엘젬백스 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
WO2015023132A1 (ko) * 2013-08-14 2015-02-19 주식회사 카엘젬백스 다발성 경화증 치료 및 예방용 조성물
ES2773296T3 (es) * 2013-10-23 2020-07-10 Gemvax & Kael Co Ltd Composición para tratar y prevenir la hiperplasia prostática benigna
WO2015072750A1 (ko) * 2013-11-12 2015-05-21 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
KR102359396B1 (ko) 2013-11-22 2022-02-08 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
CN106659149B (zh) 2014-04-30 2020-05-19 珍白斯凯尔有限公司 用于器官、组织或细胞移植的组合物、试剂盒和移植方法
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
JP6751097B2 (ja) 2015-02-27 2020-09-02 ジェムバックス アンド カエル カンパニー，リミティド 聴力損傷予防用ペプチド及びそれを含む組成物
EP3318265B1 (en) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
EP4272829A3 (en) 2016-04-07 2024-01-17 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
WO2023048530A1 (ko) * 2021-09-24 2023-03-30 주식회사 차백신연구소 종양 연관 항원으로부터 유래된 펩타이드 및 리포펩타이드와 면역활성물질로 구성되는 아쥬번트를 포함하는 항암 백신 조성물 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
WO2003038047A2 (en) 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
ITMI20032121A1 (it) * 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm Procedimento per la preparazione di imiquimod e suoi intermedi

Also Published As

Publication number Publication date
SI2310044T1 (sl) 2017-03-31
EP2310044A2 (en) 2011-04-20
JP5787752B2 (ja) 2015-09-30
HUE030984T2 (en) 2017-06-28
PT2310044T (pt) 2016-11-18
JP2011524390A (ja) 2011-09-01
CA2727388A1 (en) 2010-01-14
WO2010003520A2 (en) 2010-01-14
ES2602453T3 (es) 2017-02-21
HRP20161434T1 (hr) 2017-02-24
CA2727388C (en) 2017-08-29
CY1118215T1 (el) 2017-06-28
DK2310044T3 (en) 2016-12-12
US20110135692A1 (en) 2011-06-09
US8828403B2 (en) 2014-09-09
LT2310044T (lt) 2016-12-27
EP2310044B1 (en) 2016-08-24
WO2010003520A3 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
LT2310044T (lt) Priešvėžinė imunoterapija
WO2010080124A9 (en) Nkg2d-fc for immunotherapy
GB0813654D0 (en) Gemstone viewer
GB0815216D0 (en) Interleukin
EP2323928A4 (en) CARRIER ASSEMBLY
IL208990A0 (en) Novel phenylimidazopyrazines
GB0907413D0 (en) Novel methods
GB2451357B (en) Ceramic Armour
GB0811360D0 (en) Methods
IL200278A0 (en) Novel methods
GB2471221B (en) Methods
GB0818650D0 (en) Methods
IL207958A0 (en) Allogeneic cancer cell - based immunotherapy
GB0907601D0 (en) Novel methods
GB0810012D0 (en) Fixture means
GB0817482D0 (en) No-catch zip
GB0806577D0 (en) Fastening means
GB0812589D0 (en) Adoptive immunotherapy
GB0712715D0 (en) Adoptive immunotherapy
GB0711729D0 (en) Adoptive immunotherapy
AU2008903232A0 (en) Cancer immunotherapy
AU2009903449A0 (en) Cancer Immunotherapy
PH32008000422S1 (en) Gemstone
PH32008000431S1 (en) Gemstone
GB0811114D0 (en) Mud-monster + tail-safe